Disease relevance
Begin with well-defined nonsense-mutation contexts and disease-relevant experimental questions. β-thalassemia is an India-priority research focus.
INDIA-FIRST. GLOBALLY MINDED.
Built in India.
Designed for global science.
India-first means building scientific ownership, evidence generation and development capability here. It is a starting point for original biotechnology with a global scientific outlook.
OUR ORIGIN. OUR PURPOSE.INDIA → GLOBAL SCIENCE
CREATED WITH PURPOSERooted in India.
Rooted in India.
Engineered to continue.
KritRNA brings together कृ (kṛ), the Sanskrit root meaning “to make, create or act”, and tRNA, the molecular adaptor that helps translate genetic information into protein. Together: tRNA created with purpose, engineered to help translation continue.
Our name expresses our ambition: to build scientific ownership in India and contribute original, rigorous biotechnology to the world. Our programmes connect molecular science, computational development and evidence generation with the realities of the people they may one day serve.
Scientific ownershipAccess-aware developmentGlobal collaboration
Explore our India-first strategy ↗WHERE PURPOSE BECOMES PRACTICE
Connect the need, the science and the work.
Scientific ownership
Build original scientific capability, candidate-development knowledge and evidence from India while engaging with the global research community.
Validation relationships
Work towards formal collaborations with research laboratories, CROs, clinicians and disease-model specialists who can help generate rigorous evidence.
Access-aware development
Consider the realities of patients, healthcare systems and research infrastructure as part of programme and development decisions.
INITIAL RESEARCH PRIORITIES
HBB. DMD. TP53.
Three initial programmes, each with distinct mutation, protein-restoration, delivery and experimental questions.
β-Thalassemia
Design suppressor-tRNA candidates for selected HBB nonsense-mutation contexts and restore β-globin production.
Current milestone: Program definition. Next: Candidate design and in-vitro assay specification.
Duchenne muscular dystrophy
Design suppressor-tRNA candidates for selected DMD premature-stop contexts and restore full-length dystrophin.
Current milestone: Program definition. Next: Candidate design and reporter-assay specification.
p53-deficient cancer
Explore suppressor-tRNA strategies for selected TP53 nonsense mutations with the aim of restoring full-length p53 protein and tumour-suppressor function.
Current milestone: Program definition. Next: Mutation prioritisation and disease-relevant functional-assay planning.
EXECUTION PATHWAY
Define. Design. Validate. Learn.
Define a relevant question
Select a mutation and disease context with a clear experimental rationale.
Design candidate possibilities
Use the developing platform to support informed candidate selection.
Validate through collaboration
Challenge the candidate in appropriate assays and disease-relevant experimental systems.
Build evidence before expanding
Use reproducible molecular, protein-function and safety evidence to inform each next step.
Broader scientific context: CFTR / cystic fibrosis
CFTR nonsense mutations remain relevant to the wider suppressor-tRNA literature and the founder’s published research. They are scientific background here, rather than one of KritRNA’s current initial programmes.
Build the capability.
Build it together.
We welcome structured conversations with research laboratories, CROs, clinicians, hospitals, incubators, patient organisations and aligned investors. These are early research programmes, not a treatment or patient-enrolment pathway.
Discuss an India-based collaboration ↗